Sandercock Colin 4
4 · Cue Biopharma, Inc. · Filed Dec 5, 2025
Insider Transaction Report
Form 4
Sandercock Colin
SVP, GENERAL COUNSEL
Transactions
- Award
Stock Option (right to buy)
2025-09-26+30,000→ 30,000 totalExercise: $0.70Exp: 2034-07-23→ Common Stock (30,000 underlying) - Award
Stock Option (right to buy)
2025-12-03+70,000→ 70,000 totalExercise: $0.70Exp: 2024-07-23→ Common Stock (70,000 underlying)
Footnotes (2)
- [F1]On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested.
- [F2]On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on December 3, 2025 and these shares underlying the option vested.